Kisspeptin-10
PeptideThe medical score (52) substantially exceeds the community score (38), as clinical RCTs demonstrate significant effects on LH, sexual brain processing, and fertility [s5, s8, s9], while the biohacker community regards kisspeptin-10 as impractical, expensive, and clinically inferior to other options [c1, c2]. Low community uptake accounts for the low community score despite existing clinical evidence.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Kisspeptin-10 activates the HPG axis via GnRH neurons and has shown measurable effects on LH pulsatility, IVF ovulation induction, and sexual dysfunction in small clinical trials (n<200, Phase I/II). All validated protocols use intravenous administration under medical supervision — subcutaneous biohacker protocols have no RCT backing. The short half-life, receptor desensitization risk, and absence of long-term data make practical use outside clinical trials genuinely problematic. The community itself largely views kisspeptin-10 as an expensive niche — enclomiphene or HCG are considered better-validated alternatives.
Description
Kisspeptin-10 is an endogenous neuropeptide (10 amino acids) that activates the HPG axis via GnRH and is being investigated in reproductive medicine and sexual medicine [s1, s2].
Kisspeptin-10 (KP-10) is the smallest biologically active fragment of the KISS1 gene product and consists of 10 amino acids. It is the C-terminal core fragment sufficient for full activation of the KISS1 receptor (GPR54/KISS1R) [s1, s3]. Kisspeptin-10 is identical in pharmacological potency to the longer Kisspeptin-54, as both isoforms display equal affinity at KISS1R in in vitro binding assays [s4]. The peptide plays a central role in regulating the hypothalamic-pituitary-gonadal (HPG) axis. It is the primary physiological trigger for pulsatile GnRH release, which governs the secretion of LH (luteinizing hormone) and FSH (follicle-stimulating hormone) from the pituitary gland [s1, s2, s5]. Clinical research applications include: - Hypothalamic hypogonadism in men: Intravenous bolus doses of 1 µg/kg kisspeptin-10 produced a significant, dose-dependent increase in LH and subsequent testosterone [s5]. - Triggering oocyte maturation in IVF: Kisspeptin-10 is being investigated as an alternative to hCG to reduce the risk of ovarian hyperstimulation syndrome (OHSS) [s6, s7]. - Hypoactive sexual desire disorder (HSDD): Two RCTs demonstrated that kisspeptin improves sexual brain processing, penile tumescence, and subjective sexual desire in men and women with HSDD [s8, s9]. Kisspeptin-10 is currently in Phase I and Phase II trials worldwide but has not yet been approved as a therapeutic by the FDA or EMA [s12]. Off-label use in biohacker communities occurs subcutaneously without medical supervision, posing considerable risks [s13, s14].
Legal Status (DE)
Not approved as a medicinal product in Germany and not marketable as a dietary supplement. Kisspeptin-10 is classified as a research chemical; its sale is legal exclusively for laboratory research purposes. Human use outside of clinical trials is not permitted under current regulations. BfArM and BfR have not granted any specific approval. Peptide hormones are generally classified as prescription-required medicinal products under the AMG (Medicinal Products Act) as soon as they are used therapeutically [s12, s13].
Mechanism of Action
Kisspeptin-10 binds to the KISS1 receptor (GPR54), a G protein-coupled receptor (Gq/11 protein) expressed on GnRH-secreting neurons in the hypothalamus (particularly in the arcuate nucleus and anterior periventricular nucleus) [s1, s2, s3]. Upon receptor binding, kisspeptin-10 activates intracellular signaling cascades (phospholipase C, IP3/DAG, Ca²⁺ release), leading to depolarization of GnRH neurons and pulsatile GnRH secretion [s1, s3]. GnRH reaches the anterior pituitary via the portal vasculature and stimulates the release of LH and FSH [s2, s5]. LH acts on Leydig cells in the testes to increase testosterone production; FSH promotes spermatogenesis and follicular maturation in the female organism [s2, s5]. The effects of kisspeptin are entirely GnRH-dependent: no LH/FSH response is possible when GnRH release is blocked [s3]. Important: Continuous (non-pulsatile) infusion induces tachyphylaxis (receptor desensitization), resulting in decreased LH secretion. Low-dose continuous infusions, however, can increase LH pulse frequency [s5]. Additionally, there is evidence of direct ovarian effects (improvement of oocyte maturation) independent of the hypothalamic pathway [s6, s7]. Kisspeptin neurons express steroid receptors (ERα, ERβ, androgen receptor), thereby mediating gonadal steroid feedback to the HPG axis [s2].
Dosing
LH-Stimulation / Hypogonadismus (Forschungsprotokoll IV)
- Dose
- 1 µg/kg body weight as intravenous bolus (corresponding to approx. 70–90 µg for 70–90 kg)
- Frequency
- Einmalig oder nach Protokoll
- Route
- injektion-subkutan
- Duration
- Akutanwendung, Dosisfindungsstudie
- Timing
- Morning, fasted, under clinical monitoring
- With food
- vermeiden
Sexuelle Dysfunktion / HSDD (Forschungsprotokoll IV)
- Dose
- 1 nmol/kg intravenously (corresponding to approx. 12–15 µg/kg)
- Frequency
- Einmalig, cross-over Design
- Route
- injektion-subkutan
- Duration
- Akutanwendung
- Timing
- Under clinical monitoring
- With food
- vermeiden
Off-label subkutan (Biohacker-Kontext, nicht klinisch validiert)
- Dose
- 100–200 µg subcutaneously per dose
- Frequency
- 2–3× wöchentlich (Community-Protokoll, nicht belegt)
- Route
- injektion-subkutan
- Duration
- Nicht definiert; Langzeitsicherheit unbekannt
- Timing
- Evening (community recommendation without scientific basis)
- With food
- optional
No officially established upper limit for humans. Clinical studies have investigated doses up to 3 µg/kg IV; higher doses did not produce a greater LH response (plateau effect) [s5]. No validated safety upper limits exist for subcutaneous off-label applications.
All clinically validated protocols use intravenous administration under medical supervision [s5, s8, s9]. Subcutaneous protocols originate from the biohacker community and are not supported by RCTs [s14, s15]. Continuous infusion carries the risk of receptor desensitization (tachyphylaxis) [s5]. An intranasally administered dose (66.6 µg/day) was mentioned in individual community reports without clinical validation [c4].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Lokale Injektionsstellenreaktion (Rötung, Schwellung, Schmerz) Reported in clinical studies; typical for subcutaneously or intravenously administered peptides [s10, s11]. | gelegentlich | leicht |
| Hitzewallungen (Hot Flushes) Explicable by sudden LH surge and subsequent sex hormone fluctuations; mentioned in community reports and clinical studies [s10, s11]. | gelegentlich | leicht |
| Kopfschmerzen Documented as an adverse effect in clinical trials; mechanistically possibly mediated by vasoactive effects of the LH/GnRH cascade [s10]. | gelegentlich | leicht |
| Rezeptordesensibilisierung (Tachyphylaxie) mit Verlust der LH-Antwort Documented with continuous, non-pulsatile infusion. Clinically relevant with improper use involving frequent injections [s5]. | theoretisch | moderat |
| Hormonelle Dysregulation (übermäßige LH/FSH-Stimulation, Östrogen-Anstieg bei Männern) Elevated LH levels can lead to increased estradiol via enhanced aromatization, potentially promoting gynecomastia in men. Not systematically investigated clinically in off-label use [s2, c4]. | theoretisch | moderat |
| Ovarielles Überstimulationssyndrom (OHSS) bei Frauen (geringeres Risiko als hCG) Kisspeptin shows a lower OHSS risk than hCG in IVF studies, but does not completely exclude it [s6, s7]. | selten | schwer |
Contraindications
Kisspeptin increases LH, FSH, and sex steroids. Elevated testosterone or estrogen levels may promote growth of hormone-dependent tumors [s2, s3].
Effects on embryonic development insufficiently studied; uncontrolled hormonal stimulation is contraindicated [s6].
As with all peptide injections, risk of anaphylactic reactions exists, although rarely reported in clinical trials [s10].
PCOS patients exhibit elevated LH pulse frequency; further stimulation may lead to excessive androgen production and increased risk of OHSS [s6, s7].
Kisspeptin is a central trigger of puberty; uncontrolled stimulation prior to completion of gonadal maturation is contraindicated [s2].
Interactions
Synergistic
Kisspeptin-10 stimulates GnRH release from the hypothalamus, while enclomiphene as a selective estrogen receptor antagonist blocks negative feedback inhibition by estrogen at the hypothalamus; both mechanisms act additively to enhance endogenous LH and FSH secretion.
Kisspeptin-10 increases endogenous LH secretion via the GnRH axis, thereby stimulating testicular testosterone and sperm production, while HCG as an LH analogue directly stimulates Leydig cells; the combination can synergistically enhance gonadal steroidogenesis.
In preclinical studies, ashwagandha (Withania somnifera) demonstrated adaptogenic effects on the hypothalamic-pituitary-gonadal axis with increases in LH and testosterone, potentially augmenting kisspeptin-mediated GnRH stimulation; however, the precise molecular mechanism of this interaction has not yet been fully elucidated.
Kisspeptin-10 stimulates GnRH neurons at the hypothalamic level, while gonadorelin directly activates the GnRH receptor at the pituitary. These complementary sites of action can enhance LH and FSH secretion simultaneously at two levels. The combination is considered one of the most popular stacks for supporting the HPG axis.
Caution
Exogenous DHEA, as an androgen precursor, can amplify negative feedback on the HPG axis and attenuate kisspeptin-induced GnRH release. In women with hormonal suppression, DHEA is reported in protocol literature as an alternative, not an adjunct.
Boron increases free testosterone and may amplify the negative feedback mechanism of the HPG axis. In combination with kisspeptin-10, elevated androgen levels may suppress GnRH pulsatility, thereby attenuating the effect of kisspeptin-10. The evidence for this specific combination is purely mechanistic.
Fenugreek extracts increase androgen availability via inhibition of 5α-reductase and aromatase. Similar to boron, an increased androgen load could enhance negative feedback on kisspeptin-sensitive GnRH neurons. No clinical study on this combination is available.
Studies
Tier B — Moderate Evidence
Community Evidence
Top reported benefits
- Isolated reports of mood improvement independent of LH/testosterone effects
- Mild libido enhancement in some user experiences
- Purported support of HPG axis recovery after anabolic cycles (PCT)
- Interest as an alternative to enclomiphene in post-TRT recovery
Top reported issues
- Little or no measurable effect on testosterone levels in self-experimentation
- High cost and complex handling (reconstitution, refrigeration)
- Short half-life makes practical application difficult
- Unreliable product quality when purchasing online
- Concerns about hormonal dysregulation (estrogen elevation)
The biohacker community largely views kisspeptin-10 as an experimental niche. Several users describe enclomiphene or HCG as cheaper and better-validated alternatives for testosterone optimization [c1, c2]. Isolated reports from the PSSD and post-finasteride syndrome community describe self-experimentation for HPG axis recovery, without consistent outcomes [c4, c5]. The absence of clinically validated subcutaneous dosing protocols is identified as a key limitation.
Scientific Sources
- The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction
Xie Q, Kang Y, Zhang C, et al. (2022). Frontiers in EndocrinologyBDOI - Kisspeptin-10 Side Effects Exposed: Is This Peptide Really Safe?
Kilo Biotechnology Editorial (2024). kilobio.com (CDMO Informationsportal)CLink - The Effects of Kisspeptin-10 on Reproductive Hormone Release Show Sexual Dimorphism in Humans
Jayasena CN, Nijher GM, Chaudhri OB, et al. (2011). Journal of Clinical Endocrinology & MetabolismAPMID:21865369DOI - Kisspeptin-10 Peptide Research: Complete Guide
Cenexa Labs Editorial (2024). cenexalabs.com (Laborinformationsportal)CLink - Peptide legal in Deutschland? Rechtslage 2026 – Peptide Culture
Peptide Culture Redaktion (2026). peptide-culture.com (Informationsportal)CLink - Kisspeptin-10 PCT Guide: Restart Natural Testosterone
Redfox Peptides Editorial (2024). redfoxpeptides.is (Anbieterinformation)CLink - Kisspeptin-10 Dosage Calculator and Chart | A-Z Guide
Peptides.org Editorial (2024). peptides.org (Informationsportal)CLink - Kisspeptins Regulating Fertility: Potential Future Therapeutic Approach in Infertility Treatment
Karakida S, Mitsuhashi T, Kimura M, et al. (2025). Journal of Clinical MedicineBDOI - Effects of kisspeptin on parameters of the HPA axis
Kinsey-Jones JS, Grachev P, Li XF, Lin YS, Milligan SR, Lightman SL, O'Byrne KT (2012). EndocrineCPMID:21387128DOI - Emerging insights into Hypothalamic-pituitary-gonadal (HPG) axis regulation and interaction with stress signaling
Whirledge S, Cidlowski JA (2018). Frontiers in Neuroendocrinology [PMC Review]CLink - Kisspeptin – Wikipedia (Deutsch)
Wikipedia-Autoren (2023). Wikipedia DEDLink - Kisspeptin-10: Mechanisms and Neuroendocrine Research
Tydes Editorial Team (2024). tydes.is (Informationsportal)CLink - Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men
Jayasena CN, Abbara A, Veldhuis JD, et al. (2015). Human ReproductionAPMID:26089302DOI - Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men
Dhillo WS, Chaudhri OB, Patterson M, et al. (2011). The Journal of Clinical Endocrinology & MetabolismAPMID:21632807DOI - Use of kisspeptin to trigger oocyte maturation during in vitro fertilisation (IVF) treatment
Abbara A, Jayasena CN, Christopoulos G, et al. (2022). Frontiers in EndocrinologyBDOI - Kisspeptin therapy for infertility: clinical trials and future implications
InoviFertility Editorial (2024). inovifertility.com (Klinikblog)CLink - Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
Mills EG, Ertl N, Wall MB, et al. (2023). JAMA Network OpenAPMID:36735255DOI - Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
Mills EG, Dhillo WS, Comninos AN, et al. (2022). JAMA Network OpenADOI
Community Sources
Storage
Unopened
Store lyophilized (freeze-dried) at -20 °C, protected from light and moisture. Stability up to 24 months under proper storage conditions.
Opened
After reconstitution with bacteriostatic water, store at 2–8 °C (refrigerator). Use within 28 days is recommended. Do not freeze after reconstitution.
Notes
Peptides are sensitive to heat, light, and repeated freeze-thaw cycles. Bacteriostatic water should be discarded after 28 days. Sterile handling is required [s14].